Search

Synovial sarcoma is an aggressive cancer primarily affecting children and young adults. A new study gets to the bottom of it.

… Thursday, March 1, 2018 Summary A new study deciphers the molecular cause of an aggressive cancer primarily affecting children and young adults. Researchers at the Sloan Kettering Institute have unraveled how a genetic mutation drives a type of aggressive soft tissue cancer called synovial sarcoma .

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

… Monday, December 14, 2020 Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine, according to a retrospective analysis of patients treated at Memorial Sloan Kettering

Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care. Leaders from both institutions have confirmed the first step in announcing their recently signed agreement for Miami Cancer Institute to join the Memorial Sloan Kettering Cancer Alliance.

… Wednesday, February 10, 2016 Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.

… Thursday, October 28, 2010 An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer . The study was published today online in the open-access journal

GSK congratulates ten of its doctoral students who have been recognized by esteemed organizations for their promising academic research.

… Thursday, October 8, 2020 The Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences congratulates ten of its doctoral students — eight of them women — who have been recognized by esteemed organizations for their promising academic research. They each will receive stipend awards to support

Learn about a blood test using carbon nanotubes that could potentially detect brain tumors.

… Thursday, January 8, 2026 Imagine a blood test that detects the first signs of a  brain tumor when it might be treated more easily. A liquid biopsy for brain cancers is now one step closer to reality. The laboratory of  Memorial Sloan Kettering Cancer Center (MSK) biomedical engineer Daniel Heller, PhD

Learn about how the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center supports MSK researchers as they learn more about the number one problem in cancer research today.

… Thursday, July 1, 2021 Alan Gerry has always recognized an opportunity when he sees one. His parents both emigrated from Russia to New York City in their youth so their families could build better lives. They met while working in a garment factory on the Lower East Side and soon married and had three

Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.

… Thursday, September 18, 2014 Summary Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous. Regenerative medicine is based on the idea that stem cells could be used to regrow other cells or tissues that have been lost

Learn more about olaratumab, a promising drug that has been shown to extend survival for people with advanced soft tissue sarcoma — particularly leiomyosarcoma — by nearly a year in a phase II clinical trial.

… Monday, June 13, 2016 Summary A phase II clinical trial for sarcoma has shown that the targeted drug therapy olaratumab extends survival by nearly a year for people with advanced disease. The study’s lead investigator says the results are “unprecedented” for this rare disease, which currently has very

Results from a study of women with breast and ovarian cancer show surprisingly low rates of genetic testing.

… Tuesday, July 16, 2019 Summary A recent study in the Journal of Clinical Oncology found that only a quarter of women with breast cancer and a third of women with ovarian cancer had undergone genetic testing. MSK experts say these numbers are surprisingly low. A lot has changed since the BRCA genes were